67 related articles for article (PubMed ID: 11910979)
1. [Insulin treatment in type 2 diabetes: epidemiological data].
Papoz L
Diabetes Metab; 2001 Nov; 27(5 Pt 3):S7-14. PubMed ID: 11910979
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus.
Yki-Järvinen H
Diabetes Metab Res Rev; 2002; 18 Suppl 3():S77-81. PubMed ID: 12324990
[TBL] [Abstract][Full Text] [Related]
3. Type 1 diabetes: benefits of intensive insulin therapy. Patients should control blood glucose strictly.
Prescrire Int; 2002 Apr; 11(58):61. PubMed ID: 11987320
[TBL] [Abstract][Full Text] [Related]
4. When oral agents fail: optimizing insulin therapy in the older adult.
Meece J
Consult Pharm; 2009 Jun; 24 Suppl B():11-7. PubMed ID: 19555131
[TBL] [Abstract][Full Text] [Related]
5. [Prevalence of diabetes, antidiabetic treatment and chronic diabetic complications reported by general practitioners].
Fabian W; Majkowska L; Stefański A; Moleda P
Przegl Lek; 2005; 62(4):201-5. PubMed ID: 16229234
[TBL] [Abstract][Full Text] [Related]
6. Long-term benefits of insulin therapy and glycemic control in overweight and obese adults with type 2 diabetes.
Caballero AE
J Diabetes Complications; 2009; 23(2):143-52. PubMed ID: 18413192
[TBL] [Abstract][Full Text] [Related]
7. Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria.
Schütt M; Kern W; Krause U; Busch P; Dapp A; Grziwotz R; Mayer I; Rosenbauer J; Wagner C; Zimmermann A; Kerner W; Holl RW;
Exp Clin Endocrinol Diabetes; 2006 Jul; 114(7):384-8. PubMed ID: 16915542
[TBL] [Abstract][Full Text] [Related]
8. Insulin therapy for maximal glycemic control in type 2 diabetes mellitus.
Spellman CW
J Am Osteopath Assoc; 2007 Jul; 107(7):260-9. PubMed ID: 17682113
[TBL] [Abstract][Full Text] [Related]
9. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
10. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
[TBL] [Abstract][Full Text] [Related]
11. Inhaled human insulin: new drug. No short-term advantages, too many unknowns in the long term.
Prescrire Int; 2006 Dec; 15(86):203-9. PubMed ID: 17165235
[TBL] [Abstract][Full Text] [Related]
12. Insulin therapy in Europe.
Scherbaum WA
Diabetes Metab Res Rev; 2002; 18 Suppl 3():S50-6. PubMed ID: 12324986
[TBL] [Abstract][Full Text] [Related]
13. Pathophysiology and treatment of patients with type 2 diabetes exhibiting failure to oral drugs.
Efendic S; Alvarsson M; Brismar K; Wagner H
Acta Physiol (Oxf); 2008 Jan; 192(1):117-25. PubMed ID: 18171434
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology and costs of diabetes treated with insulin in France.
Detournay B; Raccah D; Cadilhac M; Eschwège E
Diabetes Metab; 2005 Jun; 31(3 Pt 2):3-18. PubMed ID: 16142041
[TBL] [Abstract][Full Text] [Related]
15. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
[TBL] [Abstract][Full Text] [Related]
16. Transitioning pharmacologic therapy from oral agents to insulin for type 2 diabetes.
Tanenberg RJ
Curr Med Res Opin; 2004 Apr; 20(4):541-53. PubMed ID: 15119992
[TBL] [Abstract][Full Text] [Related]
17. Feature selection and classification model construction on type 2 diabetic patients' data.
Huang Y; McCullagh P; Black N; Harper R
Artif Intell Med; 2007 Nov; 41(3):251-62. PubMed ID: 17707617
[TBL] [Abstract][Full Text] [Related]
18. Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
Massi-Benedetti M; Orsini-Federici M
Diabetes Care; 2008 Feb; 31 Suppl 2():S131-5. PubMed ID: 18227473
[TBL] [Abstract][Full Text] [Related]
19. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study.
Khutsoane D; Sharma SK; Almustafa M; Jang HC; Azar ST; Danciulescu R; Shestakova M; Ayad NM; Guler S; Bech OM;
Diabetes Obes Metab; 2008 Mar; 10(3):212-22. PubMed ID: 18269636
[TBL] [Abstract][Full Text] [Related]
20. [Metabolic control by means of insulin in patients with type 2 diabetes and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity--secondary publication].
Gustafsson I; Malmberg K; Rydén L; Wedel H; Birkeland K; Bootsma A; Dickstein K; Efendic S; Fisher M; Hamsten A; Herlitz J; Hildebrandt PR; MacLeod K; Laakso M; Torp-Pedersen CT; Waldenström A;
Ugeskr Laeger; 2006 Feb; 168(6):581-4. PubMed ID: 16476220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
